We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Synthetic Fatty Acid Derivatives Display Anti-Cancer Potential

By LabMedica International staff writers
Posted on 26 Jul 2018
Print article
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Image: A ball-and-stick model of the docosahexaenoic acid (DHA) molecule. DHA is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina (Photo courtesy of Wikimedia Commons).
Metabolites produced during digestion of omega-3 fatty acids have been found to have anti-cancer properties, and their synthetic derivatives have the potential to be developed into potent chemotherapeutic drugs.

Dietary omega-3 fatty acids, such as docosahexaenoic acid (DHA), have been shown to suppress tumor growth through their conversion to epoxide metabolites. Alternatively, DHA is converted enzymatically into docosahexaenoylethanolamide (DHEA), an endocannabinoid with anti-proliferative activity.

Investigators at the University of Illinois (Champaign-Urbana, USA) had previously described a novel class of anti-inflammatory DHEA-epoxide derivative called epoxydocospentaenoic-ethanolamide (EDP-EA) that contained both ethanolamide and epoxide moieties. To expand those findings they examined the anti-tumorigenic properties of EDP-EAs in an osteosarcoma (OS) mouse model.

The investigators showed an approximately 80% increase in EDP-EAs in metastatic versus normal lungs of mice. In addition they found significant differences in the apoptotic and anti-migratory potencies of different EDP-EA structural isomers, which were partially mediated through the cannabinoid receptor 1 (CB1). The cannabinoid receptor is represented in relatively high density on the surface of cancer cells.

The investigators then synthesized derivatives of the most pro-apoptotic isomer. These derivatives were found to display reduced hydrolytic susceptibility to fatty acid amide hydrolase (FAAH) and increased CB1-selective binding.

"We have a built-in endocannabinoid system which is anti-inflammatory and pain-reducing. Now we see it is also anti-cancer, stopping the cells from proliferating or migrating," said senior author Dr. Aditi Das, professor of comparative biosciences at the University of Illinois. "These molecules could address multiple problems: cancer, inflammation, and pain."

"The dramatic increase indicated that these molecules were doing something to the cancer - but we did not know if it was harmful or good," said Dr. Das. "We asked, are they trying to stop the cancer, or facilitating it? So we studied the individual properties and saw that they are working against the cancer in several ways. Dietary consumption of omega-3 fatty acids can lead to the formation of these substances in the body and may have some beneficial effects. However, if you have cancer, you want something concentrated and fast acting. That is where the endocannabinoid epoxide derivatives come into play - you could make a concentrated dose of the exact compound that is most effective against the cancer. You could also mix this with other drugs such as chemotherapies."

Related Links:
University of Illinois

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.